Stifel keeps Hinge Health at Buy and raises price target to $135
Stifel analysts kept their Buy rating on Hinge Health shares and lifted the price target from $130 to $135 (+3.8%), according to TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Stifel maintained its Buy rating on Hinge Health and raised the price target by 3.8%, from $130 to $135, TradingView reports. According to the publication, the new target implies a 16.9% upside from the November 2 close, when the shares were priced at $115.48.
The article also lists the four most recent analyst notes on the company over the past 30 days. Their price targets range from $110 to $140. Rating data is provided by Benzinga.
why it matters
Updates like this usually have limited market impact: they reflect one analyst's view rather than new financial results from the company. The spread of targets in recent notes, from $110 to $140, shows that market participants hold differing opinions on the stock.
tags
instruments
sources
- Stifel maintains Hinge Health at Buy, raises price target to $135 from $130 — TradingView, 3 November 2026 at 13:02 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗